103 related articles for article (PubMed ID: 36194939)
41. Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control.
Ndizeye Z; Vanden Broeck D; Lebelo RL; Bogers J; Benoy I; Van Geertruyden JP
PLoS One; 2019; 14(6):e0209303. PubMed ID: 31237894
[TBL] [Abstract][Full Text] [Related]
42. Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies.
Asangbeh-Kerman SL; Davidović M; Taghavi K; Kachingwe J; Rammipi KM; Muzingwani L; Pascoe M; Jousse M; Mulongo M; Mwanahamuntu M; Tapela N; Akintade O; Basu P; Dlamini X; Bohlius J
BMC Public Health; 2022 Aug; 22(1):1530. PubMed ID: 35948944
[TBL] [Abstract][Full Text] [Related]
43. High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas.
Teixeira MF; Sabidó M; Leturiondo AL; de Oliveira Ferreira C; Torres KL; Benzaken AS
Virol J; 2018 Feb; 15(1):36. PubMed ID: 29454382
[TBL] [Abstract][Full Text] [Related]
44. High-risk papillomavirus infection among women living with human Immunodeficiency virus: Brazilian multicentric study.
Miranda AE; Silveira MF; Travassos AG; Tenório T; Val ICC; Lannoy L; Mattos Junior HS; Carvalho NS
J Med Virol; 2017 Dec; 89(12):2217-2223. PubMed ID: 28771777
[TBL] [Abstract][Full Text] [Related]
45. [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines].
Fusté P; Santamaría X; Carreras R
Med Clin (Barc); 2008 Jun; 131(1):30-4. PubMed ID: 18582422
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and correlates of cervical HPV infection in a clinic-based sample of HIV-positive Hispanic women.
Ortiz AP; Tamayo V; Scorsone A; Soto-Salgado M; Febo I; Piovanetti P; Venegas-Ríos HL; Yamamura Y; Zorrilla C
Papillomavirus Res; 2017 Dec; 4():39-44. PubMed ID: 29179868
[TBL] [Abstract][Full Text] [Related]
47. Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
Dhokotera TG; Muchengeti M; Davidović M; Rohner E; Olago V; Egger M; Bohlius J
Int J Cancer; 2024 Jan; 154(2):284-296. PubMed ID: 37682630
[TBL] [Abstract][Full Text] [Related]
48. Cervical cancer screening uptake and correlates among HIV-infected women: a cross-sectional survey in Côte d'Ivoire, West Africa.
Tchounga B; Boni SP; Koffi JJ; Horo AG; Tanon A; Messou E; Koulé SO; Adoubi I; Ekouevi DK; Jaquet A
BMJ Open; 2019 Aug; 9(8):e029882. PubMed ID: 31473620
[TBL] [Abstract][Full Text] [Related]
49. Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology.
Videla S; Darwich L; Cañadas MP; Paredes R; Tarrats A; Castella E; Llatjos M; Bofill M; Clotet B; Sirera G;
J Acquir Immune Defic Syndr; 2009 Feb; 50(2):168-75. PubMed ID: 19131892
[TBL] [Abstract][Full Text] [Related]
50. Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?
Meys R; Gotch FM; Bunker CB
Br J Dermatol; 2010 Jan; 162(1):6-11. PubMed ID: 19709102
[TBL] [Abstract][Full Text] [Related]
51. Six-month natural history of oral versus cervical human papillomavirus infection.
D'Souza G; Fakhry C; Sugar EA; Seaberg EC; Weber K; Minkoff HL; Anastos K; Palefsky JM; Gillison ML
Int J Cancer; 2007 Jul; 121(1):143-50. PubMed ID: 17354235
[TBL] [Abstract][Full Text] [Related]
52. Effect of antiretroviral therapy on the incidence of cervical neoplasia among HIV-infected women: a population-based cohort study in Taiwan.
Chen YC; Li CY; Liu HY; Lee NY; Ko WC; Ko NY
AIDS; 2014 Mar; 28(5):709-15. PubMed ID: 24326354
[TBL] [Abstract][Full Text] [Related]
53. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men.
van der Snoek EM; van der Ende ME; den Hollander JC; Schutten M; Neumann HA; van Doornum GJ
Sex Transm Dis; 2012 Jul; 39(7):495-500. PubMed ID: 22695316
[TBL] [Abstract][Full Text] [Related]
54. HAART use in women with HIV and influence on cervical intraepithelial neoplasia: a clinical opinion.
Khanna N
J Low Genit Tract Dis; 2002 Apr; 6(2):111-5. PubMed ID: 17051009
[TBL] [Abstract][Full Text] [Related]
55. Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: a simulation.
Atashili J; Smith JS; Adimora AA; Eron J; Miller WC; Myers E
PLoS One; 2011 Apr; 6(4):e18527. PubMed ID: 21483701
[TBL] [Abstract][Full Text] [Related]
56. Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study.
Devine A; Vahanian A; Sawadogo B; Zan S; Bocoum FY; Kelly H; Gilham C; Nagot N; Ong JJ; Legood R; Meda N; Miners A; Mayaud P;
PLoS One; 2021; 16(3):e0248832. PubMed ID: 33765011
[TBL] [Abstract][Full Text] [Related]
57. Assessing the relationship between HIV infection and cervical cancer in Côte d'Ivoire: a case-control study.
Adjorlolo-Johnson G; Unger ER; Boni-Ouattara E; Touré-Coulibaly K; Maurice C; Vernon SD; Sissoko M; Greenberg AE; Wiktor SZ; Chorba TL
BMC Infect Dis; 2010 Aug; 10():242. PubMed ID: 20716343
[TBL] [Abstract][Full Text] [Related]
58. Risk factors for cervical presence of human papillomavirus DNA among women at risk for HIV infection. DIANAIDS Collaborative Study Group.
Rezza G; Giuliani M; Serraino D; Branca M; Benedetto A; Garbuglia A; Ippolito G; Franceschi S
Epidemiol Infect; 1998 Aug; 121(1):173-7. PubMed ID: 9747769
[TBL] [Abstract][Full Text] [Related]
59. Epidemiology of Cervical Squamous Intraepithelial Lesions in HIV Infected Women in Kenya: a cross-Sectional Study.
Memiah P; Makokha V; Mbuthia W; Kiiru GW; Agbor S; Odhiambo F; Ojoo S; Mbizo J; Muhula S; Mahasi G; Biadgilign S
Afr J Reprod Health; 2015 Mar; 19(1):133-9. PubMed ID: 26103703
[TBL] [Abstract][Full Text] [Related]
60. Human papillomavirus antibody response following HAART initiation among MSM.
Combes JD; Clifford GM; Egger M; Cavassini M; Hirsch HH; Hauser C; Calmy A; Schmid P; Bernasconi E; Günthard HF; Franceschi S; Waterboer T; Scherrer AU;
AIDS; 2017 Feb; 31(4):561-569. PubMed ID: 28121669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
